HN30
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life… Read more
HN30 (HN30) - Net Assets
Latest net assets as of September 2025: €-148.32K EUR
Based on the latest financial reports, HN30 (HN30) has net assets worth €-148.32K EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€153.31K) and total liabilities (€301.63K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-148.32K |
| % of Total Assets | -96.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 984.82 |
HN30 - Net Assets Trend (2021–2024)
This chart illustrates how HN30's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HN30 (2021–2024)
The table below shows the annual net assets of HN30 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-299.07K | +63.11% |
| 2023-12-31 | €-810.60K | -2060.63% |
| 2022-12-31 | €41.34K | -90.99% |
| 2021-12-31 | €459.10K | -- |
Equity Component Analysis
This analysis shows how different components contribute to HN30's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 346556300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €58.77 Million | % |
| Total Equity | €-299.07K | 100.00% |
HN30 Competitors by Market Cap
The table below lists competitors of HN30 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REPUBLIC SERVICES (RPU.SG)
STU:RPU
|
$1.93 Million |
|
RanLOS AB Series B
ST:RLOS-B
|
$1.93 Million |
|
Cortus Energy AB (publ)
ST:CE
|
$1.93 Million |
|
OCEAN-GEOLOOP AS NK -01
F:FQ4
|
$1.93 Million |
|
Current Water Technologies Inc
PINK:ENPRF
|
$1.93 Million |
|
BIORA THERAPEUT.NEW -001
F:4ZU0
|
$1.93 Million |
|
Marvel Discovery Corp
OTCQB:MARVF
|
$1.92 Million |
|
HERSHEY - Dusseldorf Stock Exchang
DU:HSY
|
$1.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HN30's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -810,603 to -299,071, a change of 511,532.
- Net income of 224,745 contributed positively to equity growth.
- Other factors increased equity by 286,787.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €224.75K | +75.15% |
| Other Changes | €286.79K | +95.89% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares HN30's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.04 | €0.06 | x |
| 2022-12-31 | €0.00 | €0.06 | x |
| 2023-12-31 | €-0.06 | €0.06 | x |
| 2024-12-31 | €-0.02 | €0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HN30 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1637.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -584.75% | 0.00% | 0.00x | 1.92x | €-2.73 Million |
| 2022 | -5964.31% | 0.00% | 0.00x | 7.18x | €-2.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.14 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €254.65K |
Industry Comparison
This section compares HN30's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HN30 (HN30) | €-148.32K | -584.75% | N/A | $1.93 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |